A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis Academic Article uri icon

Overview

MeSH Major

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Certolizumab Pegol
  • Deprescriptions
  • Methotrexate

abstract

  • The study failed to meet its primary end point. However, there were no clinically meaningful differences between the standard and reduced frequency doses of CZP plus MTX; both controlled RA more effectively than stopping CZP.

publication date

  • October 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5656933

Digital Object Identifier (DOI)

  • 10.1002/art.40196

PubMed ID

  • 28666080

Additional Document Info

start page

  • 1937

end page

  • 1948

volume

  • 69

number

  • 10